Table 1 Baseline cytogenetics among patients with known cytogenetics

From: Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

Cytogenetics, n (%)

Kd (n=381)

Vd (n=404)

High risk

97 (25.5)

113 (28.0)

 t(4;14)

50 (13.1)

61 (15.1)

 t(14;16)

10 (2.6)

9 (2.2)

 del(17p)

40 (10.5)

52 (12.9)

Standard risk

284 (74.5)

291 (72.0)

  1. Abbreviations: Kd, carfilzomib and dexamethasone; Vd, bortezomib and dexamethasone.
Back to article page